ThromboGenics and BioInvent Win “Licensing Deal of the Year” at the Scrip Awards 2009
Strategic partnership with Roche for novel anti-cancer antibody TB-403 (anti-PIGF) recognised in award
Under the terms of the deal with Roche, ThromboGenics and its co-development partner BioInvent received an upfront payment of €50 million, with an additional €450 million in potential milestones, as well as double digit royalties on future product sales. The working relationship with Roche is continuing to progress well and recently ThromboGenics and BioInvent announced positive results in a Phase Ib trial of TB-403 in patients with advanced solid tumours. The results showed positive safety and tolerability data. ThromboGenics, who discovered TB-403, receives 60% and BioInvent 40% of all revenue from the deal.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.